跳至主要内容
临床试验/IRCT2014090319025N1
IRCT2014090319025N1已完成3 期

Efficacy of Adalimumab (MabAsia) versus Humira@ on activity score of Rheumatoid Arthritis: A Randomized Clinical Trial in refractory patients

Vice Chancellor for research, Tehran University of Medical Sciences0 个研究点目标入组 105 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
105

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 80 years(—)
性别
All

入选标准

  • inclusion criteria:1-Age more 18 years old, 2- active Rheumatoid Arthritis, 3-not received Humira ® yet. exclusion criteria: 1-aminotransferase levels greater than twice the upper limit of normal and serum creatinine level more than 2mg/dL, a hemoglobin level of 8.5 mg/dL or less, platelet count less than 125000 cells/mm3, leukocyte count less than 3500 cells/mm3 3- Concomitant therapy with doses of oral corticosteroids greater than 10 mg of prednisone per day ,and NSAIDs with doses greater than the maximum dose recommended by the manufacturer

排除标准

  • 未提供

研究者

发起方
Vice Chancellor for research, Tehran University of Medical Sciences

相似试验